Table 4.
Univariate and multivariate analyses of PFS in patients.
| Characteristic | Group A (n = 25) | Group B (n = 78) | ||
|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | |||
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age, years | ||||
| ≤60 | Reference | Reference | ||
| >60 | 1.189 (0.674–2.032) | 0.573 | ||
| Sex | ||||
| Female | Reference | Reference | ||
| Male | 1.555 (0.925–2.756) | 0.112 | ||
| Tumor size (cm) | ||||
| 2–4 | Reference | Reference | ||
| ≥4 | 0.778 (0.496–1.298) | 0.331 | 1.756 (0.956–1.327) | 0.024 |
| Tumor location | ||||
| Head | Reference | Reference | ||
| Body/Tail | 0.956 (0.628–1.414) | 0.753 | ||
| PS | ||||
| 0 | Reference | Reference | ||
| 1 | 0.678 (0.325–1.425) | 0.687 | ||
| 2 | 0.965 (0.456–2.105) | 0.896 | ||
| CA 19-9 (U/ml) | ||||
| ≤37 | Reference | Reference | ||
| >37 | 2.105 (1.015–4.356) | 0.035 | 1.976 (0.945–3.975) | 0.079 |
| Preoperative therapy | ||||
| Hepaticojejunostomy | Reference | Reference | ||
| Gastrojejunostomy | 0.668 (0.279–1.582) | 0.367 | ||
| Cholecystectomy | 0.769 (0.285–1.689) | 0.516 | ||
| Chemotherapy before IRE | ||||
| Gemcitabine | Reference | Reference | ||
| S-1 | 0.685 (0.308–1.527) | 0.355 | ||
| FOLFIRINOX | 0.691 (0.320–1.490) | 0.345 | ||
| PD-L1 expression, n (%) | ||||
| Positive | Reference | Reference | ||
| Negative | 0.689 (0.318–1.489) | 0.352 | ||
| Unknown | 0.691 (0.252–1.614) | 0.381 | ||
| PD-1/L1 blockade, n (%) | ||||
| Camrelizumab | Reference | Reference | ||
| Toripalimab | 0.965 (0.725–1.268) | 0.811 | ||
| Nivolumab | 1.014 (0.774–1.337) | 0.918 | ||
| Pembrolizumab | 0.477 (0.278–1.082) | 0.085 | ||
| Atezolizumab | 0.676 (0.267–1.590) | 0.381 | ||
| Treatment | ||||
| IRE+chemotherapy | Reference | Reference | ||
| IRE+chemotherapy+PD-1/PD-L1 blockade | 0.446 (0.239–0.780) | 0.005 | 0.459 (0.248–0.824) | 0.006 |
IRE, irreversible electroporation; PFS, progression-free survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; HR, hazard ratio; CI, confidence interval; PS, performance status; CA19-9, carbohydrate antigen 19-9.